Precision BioSciences (NASDAQ:DTIL) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $60.00 target price on the stock.

Separately, BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price target on the stock in a research note on Friday.

Precision BioSciences Stock Up 26.7 %

Shares of DTIL opened at $5.70 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. Precision BioSciences has a 52 week low of $3.61 and a 52 week high of $19.43. The stock has a market capitalization of $43.72 million, a price-to-earnings ratio of 95.02 and a beta of 1.41. The stock has a fifty day moving average of $6.09 and a 200-day moving average of $8.27.

Hedge Funds Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC boosted its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,974 shares of the company’s stock after buying an additional 19,088 shares during the quarter. Geode Capital Management LLC owned approximately 0.86% of Precision BioSciences worth $591,000 as of its most recent SEC filing. 37.99% of the stock is currently owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.